HOLX eyes a Breast Health rebound in Q4, backed by leadership changes, new strategy and Endomag momentum.
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
EXAS gains edge over HOLX as rising Cologuard adoption, new launches and bullish EPS trends boost investor appeal.
HOLX is leaning into international growth with Surgical division strength and untapped demand driving momentum abroad.
In the closing of the recent trading day, Hologic (HOLX) stood at $65.37, denoting a +2.64% move from the preceding trading day.
I am initiating a Buy rating on Hologic, Inc. with a fair value of $81, as current risks are priced in. Hologic's strong diagnostic portfolio, recurring consumables revenue, and expanding assay menu support long-term growth in women's health. Short-term margin pressure from tariffs is expected, but normalization and margin expansion should resume from FY26 onward.
HOLX heads into Q3 earnings with revenue and EPS estimates down, tariff pressures mounting, and stock lagging peers.
HOLX advances breast health with AI tools like Genius Detection PRO and the upcoming Envision 3D platform.
The latest trading day saw Hologic (HOLX) settling at $63.26, representing a -2.1% change from its previous close.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
HOLX's GYN Surgical arm gains momentum with Fluent Pro, global expansion and strategic acquisitions fueling growth.
In the latest trading session, Hologic (HOLX) closed at $65.85, marking a +1.46% move from the previous day.